international

New Study: Vitamin Supplements May Not Slow GA Growth in Advanced Macular Degeneration

For years, ophthalmologists have recommended AREDS vitamins to patients with age-related macular degeneration (AMD), based on landmark studies suggesting the supplements slow progression to late stage forms of AMD. Earlier this year, an analysis of those studies, AREDS and AREDS2, found that antioxidants and vitamins slowed geographic atrophy (GA) progression toward the central macula in patients with advanced AMD. However, a new study using multimodal imaging refutes these claims.

Weiterlesen  867
New Study: Vitamin Supplements May Not Slow GA Growth in Advanced Macular Degeneration

Nanoscope: EMA grants Orphan designations to MCO-010 across 5 categories of retinal dystrophies

European Medicines Agency (EMA) grants MCO-010 five Orphan designations across a wide spectrum of retinal diseases involving photoreceptor loss, including syndromic and non-syndromic, rod- and cone-dominant, and macular dystrophies. In addition, the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for MCO-010 in Stargardt disease (SD).

Weiterlesen  2080
Nanoscope: EMA grants Orphan designations to MCO-010 across 5 categories of retinal dystrophies

Korean researchers develop world’s first wireless OLED contact lens for retinal diagnostics​

Electroretinography (ERG) is used to determine whether the retina is functioning normally. It is widely employed for diagnosing hereditary retinal diseases or assessing retinal function decline. A team of researchers at the Korea Advanced Institute of Science and Technology (KAIST) has now developed a next-generation wireless ophthalmic diagnostic technology that replaces the existing stationary, darkroom-based retinal testing method by incorporating an “ultrathin OLED” into a contact lens.

Weiterlesen  1547
Korean researchers develop world’s first wireless OLED contact lens for retinal diagnostics​

Lineage Cell Therapeutics’ OpRegen holds potential to become new treatment option for GA

Lineage Cell Therapeutics’ OpRegen (RG6501) is gaining attention as a promising one-time allogenic cell therapy for geographic atrophy (GA), following encouraging results from its Phase I/IIa trial. OpRegen’s ability to improve and stabilize vision positions it as a potential breakthrough in addressing a critical unmet need in GA management, says GlobalData, a leading data and analytics company.

Weiterlesen  4845
Lineage Cell Therapeutics’ OpRegen holds potential to become new treatment option for GA

Researchers Stimulate Retina to Reveal Never-Before-Seen Color

A multidisciplinary team from the University of California, Berkeley created a new platform called “Oz” that directly controls the human eye’s photoreceptor activity via cell-by-cell light delivery, providing new insight into the nature of human sight and vision loss. The researchers also found a way to manipulate the eye into seeing a brand-new color — a blue-green color of unparalleled saturation that they named “olo.”

Weiterlesen  3296
Researchers Stimulate Retina to Reveal Never-Before-Seen Color

GlobalData: Uveitis market to grow to $1.5 billion in the seven major markets by 2033

The uveitis market in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is set to grow from $522.5 billion in 2023 to $1.5 billion in 2033, driven by the entry of therapies with new mechanisms of action and route of administration into the market, as well as the growth of the uveitis population, forecasts GlobalData, a leading data and analytics company.

Weiterlesen  1448
GlobalData: Uveitis market to grow to $1.5 billion in the seven major markets by 2033

Molecular messenger of sight: Some of RBP3 secrets have been exposed

Scientists from the International Centre for Translational Eye Research (ICTER), Warsaw, have for the first time looked deep into the protein structure that may determine our vision - and discovered that it is much more dynamic than previously thought. RBP3 not only changes its shape depending on its load but may also play a role in protecting the retina from diseases ranging from diabetic retinopathy to retinitis pigmentosa

Weiterlesen  1735
Molecular messenger of sight: Some of RBP3 secrets have been exposed

Neurodiagnostics through Ocular Data: machineMD Secures Topcon Healthcare, Inc. as Lead Investor

machineMD, an award-winning medical device company at the forefront of neurodiagnostic innovation, today announced a strategic investment from Topcon Healthcare, Inc., a global leader in robotic diagnostics and digital solutions. This partnership aligns with Topcon Healthcare’s mission to deliver Healthcare from the Eye™, enhancing access to high-quality care while optimizing healthcare costs.

Weiterlesen  1155
Neurodiagnostics through Ocular Data: machineMD Secures Topcon Healthcare, Inc. as Lead Investor

Positive Results Demonstrate Efficacy of Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Glaucoma Patients

Iantrek Corporation has announced the publication of positive 2-year results from its prospective clinical study evaluating its proprietary bio-reinforced cyclodialysis technology. The study, published in Ophthalmology Science, confirms the long-term efficacy and safety of Iantrek’s bio-interventional platform for uveoscleral outflow enhancement in open-angle glaucoma patients undergoing combined cataract surgery.

Weiterlesen  1527
Positive Results Demonstrate Efficacy of Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Glaucoma Patients

Uveitis from Juvenile Idiopathic Arthritis: Treatment Pause Leads to High Rate of Relapse

According to a National Institutes of Health (NIH)-funded clinical study, children with juvenile idiopathic arthritis with uveitis are likely to experience disease recurrence when discontinuing adalimumab. This monoclonal antibody effectively controls the condition. However, many patients seek to stop or pause therapy due to high cost, the burden of injections, and potential, serious side effects.

Weiterlesen  1828
Uveitis from Juvenile Idiopathic Arthritis: Treatment Pause Leads to High Rate of Relapse

How do we use Spatio-Temporal Optical Coherence Tomography to assess ocular microcirculation?

Like a complex network of highways, the retinal microcirculation is a hidden system that powers the life of the eye – delivering oxygen, nourishing tissues, and allowing cells to function without disruption. New research conducted by ICTER (International Centre for Translational Eye Research / Warsaw) scientists will enable us to track every “movement” on these microscopic roads using the STOC-T (Spatio-Temporal Optical Coherence Tomography) technique.

Weiterlesen  1729
How do we use Spatio-Temporal Optical Coherence Tomography to assess ocular microcirculation?

Multifocal Contact Lenses Used to Slow Myopia in Youth Have a Lasting Effect

In a follow up study funded by the National Institutes of Health (NIH), researchers found that children who wore multifocal contact lenses to slow progression of myopia, maintained the treatment benefit after they stopped wearing the contacts as older teens. Controlling myopia progression in childhood can help to potentially decrease the risks of vision-threatening myopia complications later in life, such as retinal detachment and glaucoma.

Weiterlesen  2875
Multifocal Contact Lenses Used to Slow Myopia in Youth Have a Lasting Effect

ViGeneron Advances Retinitis Pigmentosa Therapy with Key FDA Designation and Trial Milestone

ViGeneron GmbH announced two important milestones for its novel gene therapy candidate VG901, to treat patients with retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to VG901, and the independent Data Safety Monitoring Board (DSMB) has unanimously approved dose escalation in the ongoing Phase 1b clinical trial

Weiterlesen  2672
ViGeneron Advances Retinitis Pigmentosa Therapy with Key FDA Designation and Trial Milestone

Transplantation of Human Eye Allografts (THEA) Program: Groundbreaking Investments to Develop Complete Eye Transplantation

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS), announced the teams to receive awards from its Transplantation of Human Eye Allografts (THEA) program. The agency’s commitment is up to $125 million, for a series of groundbreaking investments to develop the first-ever complete eye transplantation procedure and restore vision for the blind and visually impaired.

Weiterlesen  2065
Transplantation of Human Eye Allografts (THEA) Program: Groundbreaking Investments to Develop Complete Eye Transplantation

Stem Cells Repair Retinas in Monkey Models of Macular Holes

Human stem cell transplants successfully repaired macular holes in a monkey model. After transplantation, the macular holes were closed by continuous filling of the space with retinal tissue. This is according to a new study from researchers at the Center for Biosystems Dynamics Research at Kobe City Eye Hospital, and colleagues at other institutions. Their findings are described in a paper published in Stem Cell Reports

Weiterlesen  1624
Stem Cells Repair Retinas in Monkey Models of Macular Holes

Stargardt Macular Degeneration: First randomized, controlled gene therapy trial planned

Nanoscope Therapeutics announced a productive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of severe vision loss due to Stargardt Macular Degeneration (SMD), supporting advancement of MCO-010 to a Phase 3 registrational trial. The MCO-010 gene therapy utilizes an intraocular injection for delivery of a gene that encodes for the ambient light-sensitive MCO protein into retinal cells.

Weiterlesen  2289
Stargardt Macular Degeneration: First randomized, controlled gene therapy trial planned

Global perspectives on childhood myopia: addressing the rising epidemic

Scientists from around the world gathered recently in Seattle, Washington, at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to address the global increase in myopia. Myopia rates, especially among children, have spiked dramatically over the past few decades. The National Eye Institute (NEI) organized the meeting to facilitate international collaborations aimed at understanding what’s driving the epidemic and how to control it.

Weiterlesen  2654
Global perspectives on childhood myopia: addressing the rising epidemic
  • 1
  • 2

Kontakt zu EYEFOX

+49 (30) 4036 422 - 0

info@eyefox.com